panaloko download ios
NEW ORLEANS (AP) — A scruffy little fugitive is on the lam again in New Orleans, gaining fame as he outwits a tenacious band of citizens armed with night-vision binoculars, nets and a tranquilizer rifle. Read this article for free: Already have an account? To continue reading, please subscribe: * NEW ORLEANS (AP) — A scruffy little fugitive is on the lam again in New Orleans, gaining fame as he outwits a tenacious band of citizens armed with night-vision binoculars, nets and a tranquilizer rifle. Read unlimited articles for free today: Already have an account? NEW ORLEANS (AP) — A scruffy little fugitive is on the lam again in New Orleans, gaining fame as he outwits a tenacious band of citizens armed with night-vision binoculars, nets and a tranquilizer rifle. Scrim, a 17-pound mutt that’s mostly terrier, has become a folk hero, inspiring tattoos, T-shirts and even a ballad as he eludes capture from the posse of volunteers. And like any antihero, Scrim has a backstory: Rescued from semi-feral life at a trailer park and adopted from a shelter, the dog broke loose in April and scurried around the city until he was cornered in October and brought to a new home. Weeks later, he’d had enough. Scrim leaped out of a second-story window, a desperate act recorded in a now-viral video. Since then, despite a stream of daily sightings, he’s roamed free. The dog’s fans include Myra and Steve Foster, who wrote “Ode to Scrim” to the tune of Ricky Nelson’s 1961 hit, “I’m a Travelin’ Man.” “I’m a travelin’ dog and I’ve made a lot of stops/All over this town...” Leading the recapture effort is Michelle Cheramie, a 55-year-old former information technology professional. She lost everything — home, car, possessions — in Hurricane Katrina in 2005, and in the aftermath, found her calling rescuing pets. “I was like, ‘This is what I should be doing,’” Cheramie said. “I was born to rescue.” She launched Zeus’ Rescues, a nonprofit shelter that now averages 600 cat and dog adoptions a year and offers free pet food to anyone who needs it. She helped Scrim find the home he first escaped from. It was Cheramie’s window Scrim leaped from in November. She’s resumed her relentless mission since then, posting flyers on telephone poles and logging social media updates on his reported whereabouts. She’s invested thousands of dollars on wildlife cameras, thermal sensors and other gear. She took a course offered by the San Diego Zoo on the finer points of tranquilizing animals. And she’s developed a network of volunteers — the kind of neighbors who are willing to grid-search a city at 3 a.m. “...And at every stop I own the heart, of at least one lovely ... “ People like writer David W. Brown, who manages a crowd-sourced Google Map of all known Scrim sightings. He says the search has galvanized residents from all walks of life to come together. As they search for Scrim, they hand out supplies to people in need. “Being a member of the community is seeing problems and doing what you can to make life a little better for the people around here and the animals around you,” Brown said. And neighbors like Tammy Murray, who had to close her furniture store and lost her father to Parkinson’s disease. This search, she says, got her mojo back. “Literally, for months, I’ve done nothing but hunt this dog,” said Murray, 53. “I feel like Wile E. Coyote on a daily basis with him.” Murray drives the Zeus’ Rescues’ van towards reported Scrim sightings. She also handles a tactical net launcher, which looks like an oversized flashlight and once misfired, shattering the van’s window as Scrim sped away. After realizing Scrim had come to recognize the sound of the van’s diesel engine, Murray switched to a Vespa scooter, for stealth. “...If you’re ever in the 9th Ward stop and see/My cute little mini poodle ...” Near-misses have been tantalizing. The search party spotted Scrim napping beneath an elevated house, and wrapped construction netting around the perimeter, but an over-eager volunteer broke ranks and dashed forward, leaving an opening Scrim slipped through. Scrim’s repeated escapades have prompted near-daily local media coverage and a devoted online following. Cheramie can relate. “We’re all running from something or to something. He’s doing that too,” she said. Cheramie’s team dreams of placing the pooch in a safe and loving environment. But a social media chorus growing under the hashtag #FreeScrim has other ideas — they say the runaway should be allowed a life of self-determination. The animal rescue volunteers consider that misguided. “The streets of New Orleans are not the place for a dog to be free,” Cheramie said. “It’s too dangerous.” “... and my Shar-Pei doll down in old Treme/Waits for my return ...” Scrim was a mess when Cheramie briefly recaptured him in October, with matted fur, missing teeth and a tattered ear. His trembling body was scraped and bruised, and punctured by multiple projectiles. A vet removed one, but decided against operating to take out a possible bullet. The dog initially appeared content indoors, sitting in Cheramie’s lap or napping beside her bed. Then while she was out one day, Scrim chewed through a mesh screen, dropped 13 feet to the ground and squeezed through a gap in the fence, trotting away. Murray said Cheramie’s four cats probably spooked him. Winnipeg Jets Game Days On Winnipeg Jets game days, hockey writers Mike McIntyre and Ken Wiebe send news, notes and quotes from the morning skate, as well as injury updates and lineup decisions. Arrives a few hours prior to puck drop. “I wholeheartedly believe the gangster-ass cats were messing with him,” Murray said. Cheramie thinks they may have gotten territorial. Devastated but undeterred, the pair is reassessing where Scrim might fit best — maybe a secure animal sanctuary with big outdoor spaces where other dogs can keep him company. Somewhere, Murray says, “where he can just breathe and be.” ___ Brook is a corps member for The Associated Press/Report for America Statehouse News Initiative. Report for America is a nonprofit national service program that places journalists in local newsrooms to report on undercovered issues. Follow Brook on the social platform X: @jack_brook96 Advertisement AdvertisementLos Angeles Chargers running back Gus Edwards was ruled out for Saturday's road game against the New England Patriots with an ankle injury. Fellow Chargers running back J.K. Dobbins is close to returning from a four-game absence because of a knee injury, as he was listed questionable to play. Offensive lineman Trey Pipkins III (hip) and linebacker Denzel Perryman (groin) also have been ruled out for Saturday. Edwards, 29, has gained 365 yards rushing this season with four touchdowns, including two in Los Angeles' 34-27 victory over the Denver Broncos on Dec. 19. Dobbins, 26, gained 766 yards with eight TDs in 11 games (nine starts) during his first season with the Chargers. Dobbins joined the Chargers in the offseason while coming off an Achilles tear with the Ravens last season. The Chargers also have running backs Kimani Vidal and Hassan Haskins on the depth chart. Vidal, a rookie, has 131 yards in eight games this season, while Haskins has just 26 yards on 14 carries with a touchdown. The Chargers (9-6) can clinch a playoff berth with a win or tie against the Patriots. --Field Level MediaThe S&P 500 fell less than 0.1% after spending the day wavering between small gains and losses. The tiny loss ended the benchmark index’s three-day winning streak. The Dow Jones Industrial Average added 0.1% and the Nasdaq composite fell 0.1%. Trading volume was lighter than usual as US markets reopened following the Christmas holiday. Semiconductor giant Nvidia, whose enormous valuation gives it an outsize influence on indexes, slipped 0.2%. Meta Platforms fell 0.7%, and Amazon and Netflix each fell 0.9%. Tesla was among the biggest decliners in the S&P 500, finishing 1.8% lower. Some tech companies fared better. Chip company Broadcom rose 2.4%, Micron Technology added 0.6% and Adobe gained 0.5%. Health care stocks were a bright spot. CVS Health rose 1.5% and Walgreens Boots Alliance added 5.3% for the biggest gain among S&P 500 stocks. Several retailers also gained ground. Target rose 3%, Ross Stores added 2.3%, Best Buy rose 2.9% and Dollar Tree gained 3.8%. Traders are watching to see whether retailers have a strong holiday season. The day after Christmas traditionally ranks among the top 10 biggest shopping days of the year, as consumers go online or rush to stores to cash in gift cards and raid bargain bins. US-listed shares in Honda and Nissan rose 4.1% and 16.4% respectively. The Japanese car makers announced earlier this week that the two companies are in talks to combine. All told, the S&P 500 fell 2.45 points to 6,037.59. The Dow added 28.77 points to 43,325.80. The Nasdaq fell 10.77 points to close at 20,020.36. Wall Street also got a labour market update. US applications for unemployment benefits held steady last week, though continuing claims rose to the highest level in three years, the Labour Department reported. Treasury yields mostly fell in the bond market. The yield on the 10-year Treasury slipped to 4.58% from 4.59% late on Tuesday. Major European markets were closed, as well as Hong Kong, Australia, New Zealand and Indonesia. Trading was expected to be subdued this week with a thin slate of economic data on the calendar.
Inzaghi: ‘Inter stepped up a gear, Lautaro Martinez must relax’
Assad exit puts US at perilous crossroads in Syria
Raju reports on details of McConnell’s fall and injuries
Assad exit puts US at perilous crossroads in Syria
Cowboys WR CeeDee Lamb (shoulder) done for year
made history a year ago this month when the FDA approved Casgevy (exagamglogene autotemcel), the CRISPR-edited therapy it co-developed with , to treat sickle cell disease (SCD). A month later, the agency authorized Casgevy to treat transfusion-dependent beta thalassemia in patients 12 years and older. Yet CRISPR Therapeutics’ stock has failed to sustain the momentum it built when it reached its 52-week high of $91.10 on February 22, a day after the company reported positive fourth-quarter and full-year 2023 results. Since then, Casgevy’s patient uptake has progressed slower than analysts expected. While some have cited Casgevy’s list price of $2.2 million per course of treatment as a cost that insurers have balked at bearing, Kevin Niehoff, associate director at IPD Analytics told Managed Healthcare Executive (MHE) he believed price was less a barrier than the fact that SCD patients have many other treatment alternatives, such as stem cell or bone marrow transplants, as well as hydroxyurea. From a 52-week high of $91.10 on February 22, CRISPR Therapeutics shares have to $49.51 as of Thursday, though they Friday to $51.56 in afternoon trading as of 2 p.m. ET. Over the past month, two electronic transfer funds (ETFs) of ARK Investment Management (ARK Invest)—the high-profile firm led by chief investment officer and portfolio manager Catherine D. (Cathie) Wood—have largely been swimming against the investor tide by snapping up more than 1 million shares of CRISPR Therapeutics shares, mostly raising its stake in the company in recent weeks. From a reported market value of $352,285,403 at the end of the third quarter, ARK’s holdings in CRISPR Therapeutics climbed 16% to $409,634,402.21 as of Friday, based on its holdings of 8,273,771 shares. Most of ARK’s stake in CRISPR Therapeutics consists of the 6,453,394 shares held by Ark Invest’s , with a market value of $319,507,536.94—the seventh highest market value among the 33 companies in which ARKG holds shares—and a portfolio weight of 4.56% The remaining 1,820,377 shares valued at $90,126,865.27 are held by the firm’s . CRISPR Therapeutics holds the second largest market value among ARKG’s 37 portfolio companies—and a portfolio weight of 7.68%. Without citing CRISPR Therapeutics by name, Wood offered a likely explanation on a recent podcast for why the ARK ETFs have been bullish on the company in recent weeks. “Many healthcare analysts think that curing a disease is not going to be good business, even though it’s amazing for humanity. They think that a cure is one and done, which it is with gene editing,” Wood observed on the November 25 episode of “The Important Part: Investing with Liz Thomas.” “The old model is almost like an annuity, a regular payment monthly for that prescription, out for however long the patent lasts. We believe a cure in business terms is going to be worth two to—depending on the indication—20 times more valuable than a traditional medication,” Wood projected. “So, stay tuned for our research. We’re putting out a lot in that area because we believe it is so misunderstood.” A closer look between Wednesday and Friday, however, shows that the ARK funds followed dips in CRISPR Therapeutics’ share price late last week with selloffs of shares in the company. On Thursday, when CRSP shares from $51.24 to $51.14, ARK trimmed its holdings by 5,864 shares (down 0.1% from Wednesday), reducing its total market value by 0.3% or $1,135,639.78. But by Friday, when the stock to $49.51, ARKK and ARKG shrunk their combined holdings by 78,936 shares (down nearly 1% from Thursday), a market value decline of 4% or $17,523,136.05. So as with other investors, the ARK funds appear to have moved beyond the positive commercial momentum for Casgevy shown in third-quarter results released last month by CRISPR Therapeutics and Vertex. Vertex leads global development, manufacturing, regulatory and commercialization of Casgevy, with support from CRISPR Therapeutics. According to Vertex: • As of mid-October, 45 of the planned 75 authorized treatment centers (ATCs) have been activated in all regions of the world where Casgevy has been approved—the U.S., the European Union, Great Britain, Saudi Arabia, Bahrain, Canada, and Switzerland. • Cell collection had begun in about 40 patients, double the approximately 20 reported after the second quarter, while additional patients have received infusions. • The first $2 million in revenue has been generated from the first commercial patient dosed with Casgevy during Q3. That revenue was included within the $2.772 billion in product revenue that Vertex reported for the quarter. “We view the Casgevy progress as a (+)ve [positive] indicator of getting pts [patients] in the funnel, and expect a majority of ~40 pts will get tx’d [treated] w/in 1–2 quarters,” Maury Raycroft, PhD, equity analyst with Jefferies, projected in a November 5 research note. “It can take ~5–6mos from cell collection to tx. Pt demand is high, and VRTX is adding a 3rd manuf[acturing] facility w/ Lonza.” Raycroft added that Casgevy’s opportunity to attract patients in the Middle East region was “underappreciated and appealing,” with about 23,000 patients eligible. Following a meeting between CRISPR Therapeutics executives and Jefferies analysts at the firm’s London Healthcare Conference late last month, Raycroft reported that management “is pleased w/ how the ‘funnel’ trajectory is playing out commercially as underlying demand/interest has been very strong WW [worldwide] along w/ payer support. It’s only a mechanics question now as more centers get activated.” Writing in a November 20 research note, Raycroft and four Jefferies colleagues reported CRISPR Therapeutics executives expect momentum to build up in coming months, referring to the slow but steady and gradually progressing launch of Yescarta (axicabtagene ciloleucel), the chimeric antigen receptor T-cell (CAR-T) cancer treatment marketed by the Kite subsidiary of following FDA approval in 2017. CRISPR Therapeutics executives told Jefferies analysts the market potential for Casgevy stems from the presence of some 25,000 severe SCD patients in the U.S., another roughly 30,000 in the Middle East, and unspecified growing numbers in the U.K. & France than originally envisioned. In its third-quarter investor presentation, CRISPR Therapeutics pinpointed about 23,000 patients in Saudi Arabia and Bahrain alone, plus about 35,000 patients in the U.S. and Europe combined. “Mgmt [management] noted two areas, where they continue to invest are on global extension and capacity expansion, anticipating the demand,” Raycroft wrote adding that 2024 Casgevy-related expenses have been trending around ~$0.5 billion. Vertex shoulders 60% of costs and enjoys that percentage of profits, with the remaining 40% of costs and profits going to CRISPR Therapeutics. Also positive on Vertex’s commercial progress with Casgevy has been analyst Sami Corwin, PhD, and two colleagues at William Blair. “We view the treatment of the first commercial Casgevy patient as a milestone for the companies and believe they have established the infrastructure to support significant revenue generation in 2025 as more cell collections are converted into cell infusions,” Corwin and colleagues wrote November 5 in a research note. • shares from 74 cents to 49 cents in after-hours trading Wednesday after the company said it will carry out a 1-for-20 reverse stock split following approval by both its board and stockholders at a reconvened annual meeting held that day. Bluebird acknowledged that its primary goal is to increase the per share market price of its common stock to regain compliance with NASDAQ’s minimum bid price requirement for continued listing. The reverse stock split is expected to become effective at 5 p.m. ET on December 12, and the first reverse-split shares will start trading the following day. The drop partially wiped out a 105% gain earlier that day, from 36 cents to 74 cents, after the company announced that it reached agreement with the Center for Medicare and Medicaid Innovation(also called the CMS Innovation Center) to offer an outcomes-based agreement for the gene therapy LyfgeniaTM (lovotibeglogene autotemcel) under the Cell and Gene Therapy Access Model. • shares from $20.04 to $29.85 on December 2, after the company joined Zai Lab (NASDAQ: ZLAB; HKEX: 9688) to announce positive topline results from the pivotal Phase III PANOVA-3 trial (NCT03377491) assessing its Tumor Treating Fields (TTFields) therapy as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma. TTFields met the study’s primary endpoint by showing a statistically significant improvement in median overall survival (mOS) versus gemcitabine and nab-paclitaxel alone, Novocure said. In the intent-to-treat population, patients treated with TTFields plus gemcitabine and nab-paclitaxel had an mOS of 16.20 months vs. 14.16 months in patients treated with gemcitabine and nab-paclitaxel alone. • shares from $3.36 to $8.40 on December 2 after the company reported positive final results from the randomized Phase II trial (NCT04731467) evaluating its lead oncology drug CM24 in patients with pancreatic ductal adenocarcinoma (PDAC). Those results showed a consistent and continuous decrease of the PDAC biomarker CA19-9 in the experimental arm reaching a median percentage reduction from baseline of approximately 80%, vs. a 40% increase in the control arm. The trial assessed CM24—a humanized monoclonal antibody designed to block CEACAM1—in combination with Bristol Myers Squibb’s immune checkpoint inhibitor Opdivo (nivolumab) plus standard-of-care (SoC) chemotherapy in second-line metastatic PDAC patients vs. SoC chemotherapy alone. • shares over two days after the company said it will evaluate potential next steps for REL-1017 after acknowledging that the NMDA inhibitor was unlikely to meet with statistical significance the primary efficacy endpoint of the Phase III Reliance II trial (NCT06011577), which is assessing the drug for use in combination with other approved anti-depressants for major depressive disorder (MDD). The trial’s Independent Data Monitoring Committee (DMC) concluded during a pre-planned interim analysis that continuing Reliance II would be futile. Shares from $2.77 to 63 cents Wednesday, then Thursday to 45 cents after Mizuho Securities analyst Uy Ear downgraded the stock from “Outperform” to “Neutral” and slashed the firm’s 12-month price target 96% from $23 to $1. • shares from 95 cents to 51 cents Tuesday after the company said it entered into a definitive agreement to immediately exercise warrants to purchase up to 4,064,040 shares of common stock issued by the company on August 22, at $1 per share. The sale is designed to generate more than $4 million in gross proceeds—about double the company’s $2.168 million market capitalization. A day earlier, Revelation shares rose 25% after the FDA accepted the company’s investigational new drug (IND) application for Gemini, a proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD ). The decision allowed Revelation to launch a U.S.-based Phase Ib trial assessing Gemini as a preconditioning treatment in patients with chronic kidney disease. Revelation shares have cratered 98% over the past year, from $22.95 on December 4, 2023.Relief, defiance, anger: Families and advocates react to Biden's death row commutations
NASHVILLE, Tenn. (AP) — Brian Callahan insisted Monday he’s busy preparing to coach the Tennessee Titans against the Jacksonville Jaguars, not what controlling owner Amy Adams Strunk thinks of his first season. “It’s a bottom line business and we’ve got to show progress and we haven’t shown enough,” Callahan said. “I would like to see more and we got two more opportunities to do it.” The Titans have lost four straight after a 38-30 defeat in Indianapolis , dropping the season series to their AFC South foe. They also have lost six of seven to drop to 3-12, putting the franchise two losses from matching the most in a season set in 2014 when the NFL played a 16-game schedule. Asked if he thinks he will have to make a case to keep his job when this season ends, Callahan said he has no idea. “My job is to coach the football team and get ready to go play Jacksonville,” Callahan said. “That’s the only thing that I focus on. And anything other than that, is out of my control.” What’s working The Titans played a season-high 10 rookies in Indianapolis. Even with all that youth, they were flagged only four times matching their second-lowest total of the season. That was a huge improvement from the week before when Tennessee was penalized 12 times for 110 yards. What needs help Callahan said every time they try to fix one thing, another issue pops up. Against Indianapolis, the run defense simply disappeared . They gave up 335 yards rushing, the most in franchise history since Oct. 1, 1961. They gave up touchdown runs of 65 and 70 yards to Jonathan Taylor. A defense that entered Week 16 ranked 12th allowed Taylor to average 7.5 yards per carry and meant Anthony Richardson needed to throw just 11 passes. The Titans gave up 38 consecutive points — the third most allowed in a game all season just a week after giving up 37 in a loss to Cincinnati. Stock up TE Chig Okonkwo. He led the Titans with nine catches and 81 yards receiving — both career highs. He also scored his the second 2-point conversion of his career. He became the first tight end with nine or more receptions in a game since Delanie Walker had nine Nov. 13, 2016, against Green Bay. Stock down Mason Rudolph. Callahan defended the veteran’s three interceptions with one going off running back Tony Pollard’s hands and the third a last-gasp play to end the game and said he thought Rudolph had a good performance. That said, Rudolph’s numbers are almost a mirror image of the quarterback he replaced. Rudolph has eight touchdown passes and eight interceptions. He’s completing 63.8% of his passes and has a 78.8 passer rating. That’s nearly the same as Will Levis completing 63.7% of his passes with 12 TD passes and 12 interceptions. Callahan said turnovers from the quarterback spot has sort of been “our Achilles’ heel” swinging games. But he also hasn’t made a decision yet on who starts Sunday, saying stats don’t always paint the full picture. “My goal is to try to put the best chance to win on the field for us and we’ll see what that looks like,” Callahan said. Injuries Callahan said K Nick Folk might have a chance to be back after an abdominal injury sidelined the veteran in Indianapolis. The Titans are practicing with a walk-through Tuesday and taking Wednesday off for Christmas so the coach said he’ll have a better handle on injuries Thursday. Folk’s replacement Brayden Narveson missed a 53-yard field goal that would have given Tennessee a 10-0 lead. Folk is 21 of 22 on field goals this season. Key num ber 121 — Number of points allowed off turnovers this season. It’s the most in a season for the Titans since at least 2000, topping the 108 given up in 2015. The Titans lead the NFL with 32 turnovers, which Callahan called their biggest issue. “That’s insanity,” Callahan said. Next steps The Titans visit Jacksonville on Sunday for their final road trip, trying to avoid being swept by their division rival. Then it’s back home for the regular-season finale, hosting Houston before more changes this offseason in some form. ___ AP NFL: https://apnews.com/hub/nflUS stocks experience mixed fortunes on quiet day of trading
App launched to empower youth
Jesse Eisenberg believes 'Batman v Superman: Dawn of Justice' hurt his careerAP Trending SummaryBrief at 6:06 p.m. EST
New pro-European coalition approved in Romania amid period of political turmoil